<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316055</url>
  </required_header>
  <id_info>
    <org_study_id>RD7.5D-ER012010</org_study_id>
    <nct_id>NCT01316055</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment</brief_title>
  <official_title>A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram)
      tablets in healthy adult volunteers and those with mild and moderate renal impairment, and
      examine between group comparisons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics in normal, mildly renally impaired, and moderately renally impaired subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12).</measure>
    <time_frame>0 and 1,2,3,4,5,6,8, and 12 hours after the last dose</time_frame>
    <description>AUC(0-12) was based on blood samples taken at specified outcome measure time frame for dalfampridine-ER 7.5 mg tablets in healthy adult volunteers and people with mild or moderate renal impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Maximum Measured Plasma Concentration (Cmax) at Steady State, of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Steady State Fractional Clearance, Calculated as the Dose / AUC(0-12) (CL/Fss) of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Healthy: Dalfampridine-ER 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal: Dalfampridine-ER 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal: Dalfampridine-ER 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine-ER</intervention_name>
    <description>2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
    <arm_group_label>Healthy: Dalfampridine-ER 7.5 mg</arm_group_label>
    <arm_group_label>Mild renal: Dalfampridine-ER 7.5 mg</arm_group_label>
    <arm_group_label>Moderate renal: Dalfampridine-ER 7.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either gender between the ages of 18 and 75 years

          -  Have a body mass index (BMI) ranging between 18.5 - 35.0 kg/m2, inclusive

          -  Have adequate cognitive function to understand and sign the IRB approved informed
             consent prior to the performance of any study-specific procedures

          -  Be willing and able to comply with all trial requirements

          -  Fit into one of three 12-subject groups: normal renal function (CrCl &gt; 80 mL/min),
             mild renal impairment (CrCl 51-80 mL/min), and moderate renal impairment (CrCl 30-50
             mL/min)

          -  Have sufficient venous access to permit blood sample collection

          -  Women of childbearing potential must have a negative Î²-HCG pregnancy test at the
             Screening Visit.

        Exclusion Criteria:

          -  Women who are either pregnant or breastfeeding, and women of childbearing potential
             (i.e., has not had a hysterectomy or bilateral oophorectomy, or is not at least two
             years postmenopausal) who are engaged in active heterosexual relations and not using
             any of the following birth control methods: tubal ligation, implantable contraception
             device, oral, patch or injectible contraceptive, double barrier method, or sexual
             activity restricted to a vasectomized partner;

          -  History of seizure(s);

          -  Unstable, acute, or severe (CrCl &lt; 30 mL/min) renal failure;

          -  Clinically significant abnormal findings on the physical examination, ECG, vital
             signs, medical history, or clinical laboratory results during screening (other than
             abnormal renal values);

          -  Any unstable cardiovascular, enterohepatic, respiratory, or immunologic disorder or
             disease that may substantially affect the pharmacokinetics of Dalfampridine-ER;

          -  Known allergy to pyridine-containing substances, or any of the inactive ingredients of
             the Dalfampridine-ER tablet (colloidal silicon dioxide, hydroxypropyl methylcellulose,
             magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium
             dioxide);

          -  Participation in an investigational drug trial 30 days prior to Screening or plans to
             enroll in an investigational drug trial at any time during this study;

          -  Any medical condition including psychiatric disease that would interfere with the
             interpretation of the study results or the conduct of the study;

          -  Subject has started a new medication (prescription, vitamins, herbal medications, or
             other over-the-counter medications), or had a change in their existing medication
             within 30 days prior to screening;

          -  History of drug or alcohol abuse in the past 2 years, or tests positive for drugs of
             abuse at Screening;

          -  Donation of blood or blood components within 30 days prior to administration of
             investigational drug. The Investigator should instruct subjects who participate in
             this study not to donate blood or blood components during their participation in the
             study and up to four weeks after the completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert R Henney, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACRI - Phase 1</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <results_first_submitted>August 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject screened January, 2011. Last subject out August, 2011. Full Service Phase 1 Units.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="P2">
          <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="B2">
          <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="14.65"/>
                    <measurement group_id="B2" value="63.2" spread="7.22"/>
                    <measurement group_id="B3" value="67.1" spread="7.65"/>
                    <measurement group_id="B4" value="57.7" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12).</title>
        <description>AUC(0-12) was based on blood samples taken at specified outcome measure time frame for dalfampridine-ER 7.5 mg tablets in healthy adult volunteers and people with mild or moderate renal impairment.</description>
        <time_frame>0 and 1,2,3,4,5,6,8, and 12 hours after the last dose</time_frame>
        <population>Intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>The Steady State Area Under the Drug Concentration Time Curve From 0 to 12 Hours Post Dose AUC(0-12).</title>
          <description>AUC(0-12) was based on blood samples taken at specified outcome measure time frame for dalfampridine-ER 7.5 mg tablets in healthy adult volunteers and people with mild or moderate renal impairment.</description>
          <population>Intention to treat (ITT)</population>
          <units>hour*nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.8" lower_limit="130.4" upper_limit="190.9"/>
                    <measurement group_id="O2" value="276.5" lower_limit="241.5" upper_limit="316.7"/>
                    <measurement group_id="O3" value="415.3" lower_limit="383.8" upper_limit="449.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Maximum Measured Plasma Concentration (Cmax) at Steady State, of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</title>
        <time_frame>7 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Measured Plasma Concentration (Cmax) at Steady State, of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</title>
          <population>ITT</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.61" lower_limit="17.76" upper_limit="23.92"/>
                    <measurement group_id="O2" value="33.92" lower_limit="29.92" upper_limit="38.47"/>
                    <measurement group_id="O3" value="46.69" lower_limit="43.68" upper_limit="49.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Steady State Fractional Clearance, Calculated as the Dose / AUC(0-12) (CL/Fss) of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</title>
        <time_frame>7 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
            <description>Dalfampridine-ER 7.5 mg steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>The Steady State Fractional Clearance, Calculated as the Dose / AUC(0-12) (CL/Fss) of Dalfampridine-ER 7.5 mg Tablets in Healthy Adult Volunteers and Those With Mild and Moderate Renal Impairment and Examine Between-group Differences.</title>
          <population>ITT</population>
          <units>liter/hour</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.54" lower_limit="39.29" upper_limit="57.52"/>
                    <measurement group_id="O2" value="27.12" lower_limit="23.68" upper_limit="31.06"/>
                    <measurement group_id="O3" value="18.06" lower_limit="16.69" upper_limit="19.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Total study participation was to last for approximately 7 days consisting of 2 in-clinic confinement periods (exclusive of up to 14 days of screening), and follow-up 3 days post final discharge.</time_frame>
      <desc>All adverse events with an onset time after dosing and up to 72 hours after the last dose of study drug were considered treatment-emergent. In addition, adverse events with onset date before start of trial treatment but with worsening in intensity during the treatment period were also considered treatment-emergent.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="E2">
          <title>Mild Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
        <group group_id="E3">
          <title>Moderate Renal: Dalfampridine-ER 7.5 mg</title>
          <description>Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
Dalfampridine-ER : 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any TEAEs (treatment emergent adverse effects)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor (Acorda) has right to review and comment on proposed publications within a specified time frame, up to 60 days; multi-center trials require joint publication unless specifically permitted otherwise.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert Henney, PharmD</name_or_title>
      <organization>Vice President - Clinical Development &amp; Medical Affairs (CDMA)</organization>
      <phone>(914) 347-4300 ext 5138</phone>
      <email>hhenney@acorda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

